register

News & Trends - Pharmaceuticals

AbbVie’s phase 3 wins for Humira successor Skyrizi

Health Industry Hub | January 22, 2021 |

Pharma News: AbbVie is in a race against time as patent expiry of its Humira inflammatory diseases blockbuster draws near in 2023.

The company’s follow-up drug Skyrizi (risankizumab) is important to AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection against less expensive competitors.

In AbbVie’s latest announcements, Skyrizi demonstrated significant improvements in clinical remission and endoscopic response in two Phase 3 Crohn’s Disease induction studies, ADVANCE and MOTIVATE. The ADVANCE study enrolled patients who had an inadequate response or were intolerant to conventional and/or biologic therapy. The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.

Additionally, Skyrizi’s Phase 3 study results from the KEEPsAKE-1 and KEEPsAKE-2 clinical trials demonstrated improvements in disease activity across joint and skin symptoms among psoriatic arthritis patients paving the way for a launch in additional indications.

With Skyrizi, AbbVie hopes to cover many of the indications where Humira has become standard therapy.

At the 39th Annual JP Morgan Healthcare Conference on 12 January 2021, AbbVie CEO Richard Gonzalez indicated that the company expects global sales of more than $7B for Skyrizi by 2025.

You may also like Changing MSL value proposition accelerated by the COVID-19 pandemic


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.